Hudson Bay Capital Management LP Mersana Therapeutics, Inc. Transaction History

Hudson Bay Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$3.08 - $9.55 $1.96 Million - $6.09 Million	637,359 Added 196.11%	962,359 $3.17 Million
Q1 2023 May 16, 2023	BUY	$4.0 - $7.02 $40,000 - $70,200	10,000 Added 3.17%	325,000 $1.34 Million
Q1 2023 May 15, 2023	BUY	$4.0 - $7.02 $160,000 - $280,800	40,000 Added 14.55%	315,000 $1.29 Million
Q4 2022 Feb 14, 2023	BUY	$5.65 - $7.86 $169,500 - $235,800	30,000 Added 12.24%	275,000 $1.61 Million
Q3 2022 Nov 14, 2022	SELL	$4.63 - $8.0 $717,650 - $1.24 Million	-155,000 Reduced 38.75%	245,000 $1.66 Million
Q2 2022 Aug 12, 2022	SELL	$2.84 - $5.0 $99,400 - $175,000	-35,000 Reduced 8.05%	400,000 $1.85 Million
Q1 2022 May 16, 2022	BUY	$3.74 - $6.63 $542,300 - $961,350	145,000 Added 50.0%	435,000 $1.74 Million
Q4 2021 Feb 14, 2022	BUY	$5.48 - $9.86 $630,200 - $1.13 Million	115,000 Added 65.71%	290,000 $1.8 Million
Q3 2021 Nov 15, 2021	BUY	$8.56 - $14.47 $898,800 - $1.52 Million	105,000 Added 150.0%	175,000 $1.65 Million
Q2 2021 Aug 16, 2021	BUY	$13.28 - $18.07 $929,600 - $1.26 Million	70,000 New	70,000 $951,000

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $198M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.